Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Health Information Services

Simulations Plus, Inc. develops drug discovery and development simulation software, which is licensed to and used in the conduct of drug research for pharmaceutical companies worldwide. The Company"s other businesses are based on its proprietary software technologies and provide support for the emerging pharmaceutical enterprise.
Website: simulations-plus.com



Growth: Bad revenue growth rate -5.3%, there is slowdown compared to average historical growth rates 20.1%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +14.9%. On average the margin is decreasing unsteadily. Gross margin is high, +59.1%. In the last quarter the company beat the estimated EPS, 0.0%. The company was ahead of estimated EPS in 67% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -8.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 27.6% higher than minimum and 69.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 25.5% overvalued

Key Financials (Download financials)

Ticker: SLP
Share price, USD:  (-5.2%)15.9
year average price 17.76  


year start price 27.55 2025-06-04

max close price 27.79 2025-06-05

min close price 12.46 2025-07-18

current price 15.90 2026-06-03
Common stocks: 20 140 000

Dividend Yield:  0.0%
FCF Yield LTM: -8.4%
EV / LTM EBITDA: 25.9x
EV / EBITDA annualized: 75.7x
Last revenue growth (y/y):  +20.0%
Last growth of EBITDA (y/y):  0.0%
Historical revenue growth:  +20.1%
Historical growth of EBITDA:  +0.4%
EV / Sales: 3.9x
Margin (EBITDA LTM / Revenue): 14.9%
Fundamental value created in LTM:
Market Cap ($m): 320
Net Debt ($m): -35
EV (Enterprise Value): 285
Price to Book: 2.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-08prnewswire.com

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

2026-02-05globenewswire.com

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

2026-02-03prnewswire.com

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

2026-01-29prnewswire.com

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

2026-01-26newsfilecorp.com

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

2026-01-25newsfilecorp.com

ROSEN, A LEADING NATIONAL FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

2026-01-23prnewswire.com

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

2026-01-21seekingalpha.com

Simulations Plus, Inc. (SLP) Analyst/Investor Day Transcript

2026-01-21businesswire.com

Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day

2026-01-18newsfilecorp.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q4 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-11-30 2025-08-31 2025-05-31 2025-02-28 2024-08-31 2024-05-31 2024-02-29 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30 2022-08-31 2021-08-31
symbol SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2026-01-09 2025-07-15 2025-04-04 2024-07-08 2024-04-05 2024-01-05 2023-07-07 2023-04-07 2023-01-06
acceptedDate 2026-01-09 16:07:11 2025-12-01 16:16:05 2025-07-15 08:02:18 2025-04-04 07:55:42 2024-10-30 16:26:15 2024-07-08 08:56:32 2024-04-05 08:44:37 2024-01-05 07:11:27 2023-10-27 07:26:05 2023-07-07 06:08:32 2023-04-07 08:51:45 2023-01-06 16:04:40 2022-10-28 08:23:36 2021-10-27 16:15:58
calendarYear 2026 2025 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 18M 79M 20M 22M 70M 19M 18M 15M 60M 16M 16M 12M 54M 46M
costOfRevenue 8M 33M 7M 9M 27M 5M 5M 5M 12M 3M 3M 3M 11M 11M
grossProfit 11M 46M 13M 13M 43M 13M 13M 10M 48M 13M 13M 9M 43M 36M
grossProfitRatio 0.591 0.64 0.585 0.715 0.722 0.679 0.818 0.834 0.777
researchAndDevelopmentExpenses 3M 7M 1M 2M 6M 1M 1M 1M 5M 945 000 1M 1M 3M 4M
generalAndAdministrativeExpenses 4M 21M 6M 5M 22M 8M 6M 6M 28M 0 0 0 20M 0
sellingAndMarketingExpenses 3M 12M 3M 4M 9M 2M 2M 2M 7M 0 0 0 5M 0
sellingGeneralAndAdministrativeExpenses 7M 33M 9M 8M 31M 10M 7M 8M 35M 8M 8M 7M 25M 21M
otherExpenses 0 77M 77M 0 0 -1 000 000 0 1M 0 843 000 1M 0 0 0
operatingExpenses 10M 117M 87M 10M 37M 11M 9M 9M 39M 9M 9M 8M 28M 25M
costAndExpenses 18M 150M 95M 20M 64M 17M 14M 14M 51M 12M 12M 11M 39M 35M
interestIncome 267 000 722 000 170 000 154 000 4M 2M 1M 1M 4M 1M 985 000 771 000 717 000 201 000
interestExpense 0 0 0 0 0 0 0 0 0 1M -2M 213 200 0 22 000
depreciationAndAmortization 1M 8M 2M 2M 6M 1M 1M 1M 4M -2M 935 000 923 000 4M 4M
ebitda 2M 15M 5M 5M 12M 3M 6M 960 000 13M 4M 4M 878 000 19M 15M
ebitdaratio 0.126 0.261 0.222 0.169 0.303 0.066 0.252 0.256 0.073
operatingIncome 713 000 -71M -74M 3M 6M 2M 4M 960 000 9M 6M 3M -45 000 15M 11M
operatingIncomeRatio 0.039 -3.645 0.121 0.101 0.243 0.066 0.367 0.197 -0.004
totalOtherIncomeExpensesNet 257 000 1M 182 000 796 000 6M 2M 810 000 1M 3M -1M 2M 2M 204 000 -168 000
incomeBeforeTax 970 000 -69M -74M 4M 12M 4M 5M 2M 12M 5M 5M 2M 15M 11M
incomeBeforeTaxRatio 0.053 -3.636 0.156 0.21 0.287 0.166 0.304 0.322 0.135
incomeTaxExpense 294 000 -5M -7M 434 000 2M 753 000 1M 461 000 2M 932 000 894 000 373 000 3M 1M
netIncome 676 000 -65M -67M 3M 10M 3M 4M 2M 10M 4M 4M 1M 12M 10M
netIncomeRatio 0.037 -3.306 0.137 0.169 0.22 0.134 0.247 0.265 0.104
eps 0.034 -3.22 -3.35 0.15 0.5 0.16 0.2 0.098 0.5 0.2 0.21 0.06 0.62 0.49
epsdiluted 0.033 -3.35 0.15 0.15 0.2 0.096 0.2 0.2 0.06
weightedAverageShsOut 20M 20M 20M 20M 20M 20M 20M 20M 20M 20M 20M 20M 20M 20M
weightedAverageShsOutDil 20M 20M 20M 20M 20M 20M 20M 20M 20M 20M 21M 21M 21M 21M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-12-01 2024-10-30 2023-10-27 2022-10-28 2021-10-27
fiscalYear 2025 2024 2023 2022 2021
netInterestIncome 722 000 4M 4M 717 000 179 000
ebit 6M 6M 9M 15M 11M
nonOperatingIncomeExcludingInterest -77M 0 -500 000 -204 000 146 000
netIncomeFromContinuingOperations -65M 10M 10M 12M 10M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -65M 10M 10M 12M 10M
epsDiluted -3.22 0.49 0.49 0.6 0.47

Balance Sheet Statement

Property 2025 q4 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-11-30 2025-08-31 2025-05-31 2025-02-28 2024-08-31 2024-05-31 2024-02-29 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30 2022-08-31 2021-08-31
symbol SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2026-01-09 2025-07-15 2025-04-04 2024-07-08 2024-04-05 2024-01-05 2023-07-07 2023-04-07 2023-01-06
acceptedDate 2026-01-09 16:07:11 2025-12-01 16:16:05 2025-07-15 08:02:18 2025-04-04 07:55:42 2024-10-30 16:26:15 2024-07-08 08:56:32 2024-04-05 08:44:37 2024-01-05 07:11:27 2023-10-27 07:26:05 2023-07-07 06:08:32 2023-04-07 08:51:45 2023-01-06 16:04:40 2022-10-28 08:23:36 2021-10-27 16:15:58
calendarYear 2026 2025 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 30M 31M 27M 11M 10M 109M 37M 40M 58M 55M 39M 49M 52M 37M
shortTermInvestments 6M 2M 2M 10M 10M 10M 71M 74M 58M 67M 76M 82M 77M 87M
cashAndShortTermInvestments 36M 32M 28M 21M 20M 119M 109M 114M 115M 122M 115M 132M 128M 124M
netReceivables 12M 15M 15M 16M 9M 14M 16M 10M 10M 10M 11M 12M 14M 13M
inventory 0 0 0 0 0 0 1 37 000 804 000 0 397 000 992 000 1M 1M
otherCurrentAssets 10M 3M 9M 9M 8M 2M 4M 5M 4M 5M 4M 5M 3M 2M
totalCurrentAssets 58M 52M 52M 47M 39M 136M 128M 130M 130M 137M 131M 149M 147M 139M
propertyPlantEquipmentNet 1M 1M 1M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 3M
goodwill 44M 44M 43M 96M 96M 19M 19M 19M 19M 13M 13M 13M 13M 13M
intangibleAssets 29M 29M 30M 56M 59M 33M 33M 33M 33M 27M 26M 26M 26M 25M
goodwillAndIntangibleAssets 73M 73M 74M 153M 155M 52M 52M 52M 52M 40M 39M 39M 39M 38M
longTermInvestments 0 0 0 0 0 33M 9M 0 0 -110 000 0 0 0 0
taxAssets 5M 5M 7M 0 11M 3M 2M 2M 8M 110 000 2M 1M 2M 2M
otherNonCurrentAssets 1M 1M 430 000 454 999 542 000 -32M 524 000 430 000 424 999 516 000 -1M -886 000 438 999 51 000
totalNonCurrentAssets 80M 80M 83M 155M 168M 57M 66M 56M 62M 42M 42M 42M 44M 42M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 138M 132M 134M 201M 208M 193M 194M 186M 193M 179M 173M 190M 191M 182M
accountPayables 863 000 470 000 2M 1M 602 000 658 000 360 000 317 000 144 000 357 000 350 000 238 000 225 000 387 000
shortTermDebt 179 000 206 000 269 000 313 000 475 000 820 000 425 000 420 000 442 000 330 000 432 000 448 000 461 000 382 000
taxPayables 2M 2M 954 000 1M 2M 4M 1M 37 000 804 000 793 000 397 000 992 000 1M 1M
deferredRevenue 6M 3M 4M 3M 2M 1M 2M 3M 3M 3M 2M 3M 3M 651 000
otherCurrentLiabilities 2M 1M 3M 4M 4M 5M 11M 5M 4M 5M 3M 4M 931 000 10M
totalCurrentLiabilities 10M 7M 10M 11M 12M 11M 15M 9M 12M 9M 6M 8M 8M 12M
longTermDebt 378 000 0 450 000 483 000 0 512 000 607 000 669 000 0 612 000 747 000 844 000 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 -110 000 2M 1M 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 701 000 13M 0 0 0 7M 110 000 2M 1M 4M 3M
otherNonCurrentLiabilities 0 0 0 0 0 0 2M 4M 3M 110 000 -2M -1M 0 0
totalNonCurrentLiabilities 378 000 410 000 449 999 1M 13M 512 000 2M 5M 11M 722 000 3M 2M 5M 4M
otherLiabilities 0 0 0 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 378 000 410 000 450 000 483 000 531 000 922 000 607 000 1M 755 000 942 000 1M 1M 943 000 896 000
totalLiabilities 11M 7M 11M 12M 25M 12M 17M 13M 23M 10M 9M 10M 12M 16M
preferredStock 0 0 0 0 0 1 0 0 0 0 0 0 0 0
commonStock 20 000 20 000 20M 156M 20 000 150M 148M 147M 145M 144M 138M 140M 139M 133M
retainedEarnings -34M -34M -34M 34M 30M 31M 29M 26M 25M 26M 27M 40M 40M 32M
accumulatedOtherComprehensiveIncomeLoss -277 000 -271 000 -274 000 -315 000 -251 000 -305 000 -210 000 -195 000 -141 000 -134 000 -278 000 -255 000 -308 000 -43 000
othertotalStockholdersEquity 161M 138M 0 0 0 0 0 0 0
totalStockholdersEquity 127M 125M 124M 190M 182M 181M 177M 172M 170M 169M 165M 180M 178M 166M
totalEquity 127M 125M 124M 190M 182M 181M 177M 172M 170M 169M 165M 180M 178M 166M
totalLiabilitiesAndStockholdersEquity 138M 134M 201M 193M 194M 186M 179M 173M 190M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 138M 132M 134M 201M 208M 193M 194M 186M 193M 179M 173M 190M 191M 182M
totalInvestments 6M 2M 2M 10M 10M 10M 80M 74M 58M 67M 76M 82M 77M 87M
totalDebt 557 000 616 000 719 000 796 000 1M 922 000 1M 1M 1M 942 000 1M 1M 1M 1M
netDebt -30M -30M -26M -10M -9M -108M -36M -39M -56M -54M -38M -48M -50M -36M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-12-01 2024-10-30 2023-10-27 2022-10-28 2021-10-27
fiscalYear 2025 2024 2023 2022 2021
accountsReceivables 15M 9M 10M 14M 13M
otherReceivables 0 0 0 0 0
prepaids 2M 2M 0 0 0
totalPayables 470 000 602 000 144 000 225 000 387 000
otherPayables 0 0 0 0 0
accruedExpenses 2M 5M 4M 3M 0
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 410 000 531 000 755 000 943 000 896 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 159M 152M 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q4 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-11-30 2025-08-31 2025-05-31 2025-02-28 2024-08-31 2024-05-31 2024-02-29 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30 2022-08-31 2021-08-31
symbol SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP SLP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2026-01-09 2025-07-15 2025-04-04 2024-07-08 2024-04-05 2024-01-05 2023-07-07 2023-04-07 2023-01-06
acceptedDate 2026-01-09 16:07:11 2025-12-01 16:16:05 2025-07-15 08:02:18 2025-04-04 07:55:42 2024-10-30 16:26:15 2024-07-08 08:56:32 2024-04-05 08:44:37 2024-01-05 07:11:27 2023-10-27 07:26:05 2023-07-07 06:08:32 2023-04-07 08:51:45 2023-01-06 16:04:40 2022-10-28 08:23:36 2021-10-27 16:15:58
calendarYear 2026 2025 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome 676 000 -65M -67M 3M 10M 3M 4M 2M 10M 4M 4M 1M 12M 10M
depreciationAndAmortization 1M 8M 2M 2M 6M 1M 1M 1M 4M 945 000 935 000 923 000 4M 4M
deferredIncomeTax 168 000 -5M -7M -947 000 -2M -481 000 -497 000 -388 000 -2M -2M 403 000 0 -270 000 -628 000
stockBasedCompensation 2M 6M 1M 2M 7M 2M 2M 1M 5M 1M 1M 1M 3M 3M
changeInWorkingCapital 360 000 -3M 2M 5M -4M 915 000 -636 000 -3M 5M 4M -924 000 2M -3M 974 000
accountsReceivables -2M -581 000 2M -4M 3M 3M -3M -145 000 4M 1M 301 000 2M -4M -2M
inventory 0 0 0 0 0 0 0 0 0 2M 0 0 0 3M
accountsPayables 393 000 -132 000 457 000 86 000 -477 000 298 000 43 000 173 000 -81 000 7000 112 000 13 000 -162 000 39 000
otherWorkingCapital 2M -2M -547 000 4M -7M -2M 2M -3M 1M 1M -1M -560 000 1M 210 000
otherNonCashItems 69 000 76M 77M -6M -3M 108 000 24 000 -559 000 219 000 -215 000 -311 000 -38 000 2M 3M
netCashProvidedByOperatingActivities 4M 18M 8M 6M 13M 6M 6M 162 000 22M 9M 6M 5M 18M 19M
investmentsInPropertyPlantAndEquipment -900 000 -713 000 -297 000 -66 000 -566 000 -959 000 -2M -1M -4M -1M -1M -1M -4M -5M
acquisitionsNet 0 0 0 0 -99M 0 7M 1M -8M 1M 0 933 000 3M 3M
purchasesOfInvestments -6M -7M -2M -2M -67M -9M -27M -31M -95M -25M -18M -30M -101M -122M
salesMaturitiesOfInvestments 2M 15M 10M 3M 116M 80M 21M 15M 115M 34M 24M 24M 109M 100M
otherInvestingActivites 0 -793 000 -865 000 70M -7M -1M -1M 0 -933 000
netCashUsedForInvestingActivites -5M 8M 684 000 70M -8M -17M 8M 5M -6M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 2000 7000 0 164 000 146 000 164 000 0 0 758 000
commonStockRepurchased 0 0 0 0 0 0 0 0 -20M 0 0 0 0 0
dividendsPaid 0 0 0 -1M -1M -1M -1M -1M -1M
otherFinancingActivites 0 0 -2M -2M 146 000 164 000 572 000 -20M 0
netCashUsedProvidedByFinancingActivities 2000 7000 -2M -4M -1M -1M -628 000 -21M -460 000
effectOfForexChangesOnCash 0 0 0 0 0 0 4M 0 0 -15M 0 0 0 0
netChangeInCash -664 000 21M 16M 5M -47M 72M -3M -18M 6M 16M -10M -2M 15M -12M
cashAtEndOfPeriod 30M 31M 27M 11M 10M 109M 37M 40M 58M 55M 39M 49M 52M 37M
cashAtBeginningOfPeriod 31M 10M 11M 6M 58M 37M 40M 58M 52M 39M 49M 52M 37M 49M
operatingCashFlow 4M 18M 8M 6M 13M 6M 6M 162 000 22M 9M 6M 5M 18M 19M
capitalExpenditure 0 -713 000 -297 000 -66 000 -566 000 -959 000 -2M -1M -4M -1M -1M -1M -4M -5M
freeCashFlow 4M 17M 8M 6M 13M 5M 4M -936 000 18M 7M 5M 4M 14M 15M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-12-01 2024-10-30 2023-10-27 2022-10-28 2021-10-27
fiscalYear 2025 2024 2023 2022 2021
otherInvestingActivities -4M -4M 0 -3M -3M
netCashProvidedByInvestingActivities 4M -54M 7M 4M -27M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 430 000 731 000 -20M 891 000 1M
netCommonStockIssuance 430 000 731 000 -20M 891 000 1M
commonStockIssuance 430 000 731 000 0 891 000 1M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 -5M -5M -5M -5M
commonDividendsPaid 0 -5M -5M -5M -5M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -2M -3M 2M -4M -1M
netCashProvidedByFinancingActivities -1M -7M -23M -8M -5M
incomeTaxesPaid 1M 6M 3M 3M 2M
interestPaid 0 0 0 0 0

Earning call transcript

2025 q4
2026-01-08 ET (fiscal 2026 q1)
2025 q3
2025-12-01 ET (fiscal 2025 q4)
2025 q2
2025-07-14 ET (fiscal 2025 q3)
2025 q1
2025-04-03 ET (fiscal 2025 q2)
2024 q4
2025-01-07 ET (fiscal 2025 q1)
2024 q3
2024-10-23 ET (fiscal 2024 q4)
2024 q2
2024-07-02 ET (fiscal 2024 q3)
2024 q1
2024-04-03 ET (fiscal 2024 q2)
2023 q4
2024-01-03 ET (fiscal 2024 q1)
2023 q3
2023-10-25 ET (fiscal 2023 q4)
2023 q2
2023-07-06 ET (fiscal 2023 q3)
2023 q1
2023-04-05 ET (fiscal 2023 q2)
2022 q4
2023-01-04 ET (fiscal 2023 q1)
2022 q3
2022-10-26 ET (fiscal 2022 q4)
2022 q2
2022-07-06 ET (fiscal 2022 q3)
2022 q1
2022-04-06 ET (fiscal 2022 q2)
2021 q4
2022-01-06 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-04-21 11:55 ET
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
2026-04-20 11:55 ET
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
2026-04-09 ET
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
2026-03-26 ET
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
2026-03-26 ET
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
2026-03-03 ET
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
2026-02-09 ET
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
2026-02-03 ET
Simulations Plus to Participate in Upcoming Investor Conferences
2026-01-21 ET
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
2026-01-08 21:05 ET
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
2025-12-18 12:50 ET
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
2025-12-17 12:50 ET
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
2025-12-09 12:55 ET
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
2025-12-01 21:05 ET
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
2025-10-22 ET
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
2025-08-27 ET
Simulations Plus to Participate in Upcoming Investor Conferences
2025-07-29 ET
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design
2025-07-14 ET
Simulations Plus Invests in Clinical Development Technology Company Nurocor
2025-07-14 ET
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
2025-06-18 ET
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
2025-06-12 ET
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
2025-06-11 ET
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
2025-06-05 ET
Simulations Plus Releases ADMET Predictor® 13
2025-05-15 ET
Simulations Plus Releases DILIsym® 11
2025-04-21 ET
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
2025-04-03 ET
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
2025-03-20 ET
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
2025-03-10 ET
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
2025-02-04 ET
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
2025-01-22 ET
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
2025-01-13 ET
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
2025-01-07 ET
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
2024-12-17 ET
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
2024-11-19 ET
Simulations Plus to Participate in the BTIG Digital Health Forum
2024-11-13 ET
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
2024-11-06 ET
Simulations Plus to Participate in the Stephens Annual Investment Conference
2024-10-30 ET
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
2024-10-23 20:06 ET
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
2024-10-09 20:06 ET
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
2024-10-08 12:30 ET
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
2024-08-28 12:30 ET
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-23 12:00 ET
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
2024-08-01 12:30 ET
Simulations Plus Releases DILIsym® X
2024-07-30 12:30 ET
Simulations Plus Releases ADMET Predictor® Version 12
2024-07-25 12:30 ET
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
2024-07-11 12:30 ET
Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
2024-07-02 20:06 ET
Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
2024-06-20 12:30 ET
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
2024-06-18 12:30 ET
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
2024-06-12 12:58 ET
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
2024-06-12 12:00 ET
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
2024-05-22 12:30 ET
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
2024-05-15 12:30 ET
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
2024-04-04 12:30 ET
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
2024-04-03 20:34 ET
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
2024-03-20 20:06 ET
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
2024-03-13 12:30 ET
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
2024-03-05 13:30 ET
Simulations Plus and the University of Bath Awarded New FDA Grant
2024-02-15 13:30 ET
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
2024-02-13 14:15 ET
Simulations Plus Launches Corporate Development Initiative
2024-02-06 13:30 ET
Simulations Plus to Participate in Upcoming Healthcare Conferences
2024-01-30 13:30 ET
Simulations Plus Releases GastroPlus® Version 9.9
2024-01-09 13:30 ET
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
2024-01-03 21:06 ET
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
2024-01-03 21:05 ET
Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
2023-12-20 13:30 ET
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
2023-11-14 13:00 ET
Simulations Plus Outlines Paths to Win at 2023 Investor Day
2023-11-08 13:30 ET
ISoP New Board of Trustees Members Announced
2023-10-31 12:30 ET
Simulations Plus to Host Investor Day on Tuesday, November 14th
2023-10-25 20:06 ET
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
2023-10-11 20:06 ET
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
2023-09-21 12:30 ET
Simulations Plus Receives New FDA Grant Award
2023-09-07 12:30 ET
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
2023-08-24 12:30 ET
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
2023-08-15 12:30 ET
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
2023-07-13 12:30 ET
Simulations Plus Releases ADMET Predictor® 11
2023-07-06 20:06 ET
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
2023-06-21 20:06 ET
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
2023-06-20 12:00 ET
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
2023-05-10 12:30 ET
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
2023-04-18 12:30 ET
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
2023-04-05 20:06 ET
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
2023-03-30 12:30 ET
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
2023-03-28 12:30 ET
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
2023-03-21 20:06 ET
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
2023-03-16 12:30 ET
Simulations Plus to Present at Sidoti March Small-Cap Conference
2023-03-15 12:30 ET
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
2023-03-09 13:30 ET
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
2023-03-07 13:30 ET
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
2023-02-28 13:30 ET
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
2023-02-16 13:30 ET
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
2023-02-09 13:30 ET
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
2023-01-12 13:30 ET
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
2023-01-11 23:14 ET
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
2023-01-11 ET
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
2023-01-04 21:06 ET
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
2022-12-19 21:06 ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call
2022-11-15 13:30 ET
Simulations Plus and the University of Bath Awarded New FDA Grant
2022-11-10 13:30 ET
Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship Program
2022-11-03 12:30 ET
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
2022-11-03 ET
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
2022-11-02 12:30 ET
Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
2022-10-26 20:06 ET
Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results
2022-10-20 20:15 ET
Simulations Plus Announces Cash Dividend
2022-10-12 12:30 ET
Simulations Plus Releases GastroPlus® Version 9.8.3
2022-10-11 20:06 ET
Simulations Plus Sets Date for Fourth Quarter and Fiscal Year 2022 Earnings Release and Conference Call
2022-09-14 12:30 ET
Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference
2022-09-07 12:30 ET
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
2022-08-31 12:30 ET
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
2022-08-04 12:30 ET
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
2022-07-26 12:30 ET
Simulations Plus Presented New Scientific Developments at PAGE 2022
2022-07-21 12:30 ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
2022-07-14 12:30 ET
Simulations Plus Realizes Early Success with its Concierge Program
2022-07-06 20:06 ET
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
2022-06-30 12:30 ET
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
2022-06-23 12:30 ET
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
2022-06-21 20:06 ET
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
2022-06-16 12:30 ET
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
2022-05-26 12:30 ET
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
2022-05-05 12:30 ET
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
2022-04-28 12:30 ET
Simulations Plus Successfully Delivers FDA-Funded Project
2022-04-21 12:30 ET
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
2022-04-19 12:30 ET
Simulations Plus to Present at the Berenberg Discover AI Seminar
2022-04-06 20:06 ET
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
2022-03-29 12:30 ET
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
2022-03-24 12:30 ET
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
2022-03-22 20:10 ET
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
2022-03-17 12:30 ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
2022-03-10 13:30 ET
Simulations Plus Releases MembranePlus 3.0
2022-03-08 13:30 ET
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
2022-03-02 13:30 ET
Simulations Plus to Present at Raymond James Institutional Investors Conference
2022-02-08 13:30 ET
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2022-01-20 13:30 ET
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
2022-01-13 13:30 ET
Simulations Plus Enters New Collaboration with Leading Animal Health Company
2022-01-12 13:30 ET
Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference
2022-01-06 21:06 ET
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
2022-01-05 13:30 ET
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1
2021-12-20 21:10 ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
2021-12-02 13:30 ET
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
2021-11-30 15:00 ET
Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit Dispensary of Hope
2021-11-30 13:30 ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
2021-11-19 13:30 ET
Simulations Plus Names Sharlene Evans to Board of Directors
2021-11-18 13:30 ET
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
2021-11-16 13:30 ET
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
2021-10-28 12:30 ET
Simulations Plus Releases GastroPlus® Version 9.8.2
2021-10-26 12:30 ET
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products
2021-10-25 20:06 ET
Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results
2021-10-21 12:30 ET
Simulations Plus Announces the University+ Program
2021-10-13 12:30 ET
Simulations Plus Announces Cash Dividend
2021-10-11 20:15 ET
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
2021-09-23 12:30 ET
Simulations Plus Receives New Grant Award From the FDA
2021-09-15 12:30 ET
Simulations Plus Releases ADMET Predictor® (X.3)
2021-09-08 12:30 ET
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
2021-08-19 12:30 ET
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
2021-08-04 12:30 ET
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
2021-07-12 20:05 ET
Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results
2021-07-08 12:30 ET
Simulations Plus Celebrates 25 Years in Business
2021-06-28 20:15 ET
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
2021-06-17 12:30 ET
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)
2021-05-27 12:30 ET
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
2021-05-13 12:30 ET
Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference
2021-05-12 12:30 ET
Simulations Plus Uplisted to The Nasdaq Global Select Market®
2021-04-27 12:30 ET
Simulations Plus Releases ADMET Predictor® (X.2)
2021-04-20 12:30 ET
U.S. FDA Renews Licenses of DILIsym Software
2021-04-12 20:05 ET
Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results
2021-04-07 12:30 ET
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company
2021-03-29 20:05 ET
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call
2021-03-16 12:30 ET
Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium
2021-03-11 13:30 ET
Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions
2021-03-09 13:30 ET
Simulations Plus to Present at Oppenheimer Healthcare Conference
2021-02-23 13:30 ET
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration
2021-02-11 13:30 ET
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
2021-02-09 13:30 ET
Simulations Plus Releases GastroPlus® Version 9.8.1
2021-02-02 13:30 ET
Simulations Plus Enters Agreement with Distributor in China
2021-01-26 13:30 ET
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences
2021-01-14 13:30 ET
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics
2021-01-12 13:45 ET
Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference
2021-01-12 13:30 ET
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments
2021-01-11 21:05 ET
Simulations Plus Reports Record First Quarter FY2021 Financial Results
2021-01-05 13:30 ET
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
2021-01-04 13:30 ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call
2020-12-16 13:30 ET
Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report
2020-12-03 13:30 ET
DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting
2020-12-01 21:05 ET
Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer
2020-11-16 21:05 ET
Simulations Plus Reports FY2020 and Fourth Quarter FY2020 Financial Results
2020-11-10 13:30 ET
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment
2020-11-09 13:30 ET
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call
2020-11-05 13:30 ET
Simulations Plus to Participate in the Credit Suisse Virtual Healthcare Conference
2020-11-03 13:30 ET
Lixoft Expands MonolixSuite™ in Version 2020R1
2020-10-27 12:30 ET
First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review
2020-10-20 12:30 ET
Simulations Plus Releases GastroPlus® Version 9.8
2020-10-13 12:30 ET
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
2020-10-13 12:30 ET
Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA
2020-09-29 12:30 ET
Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®
2020-09-22 12:30 ET
Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®
2020-09-15 12:30 ET
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
2020-09-02 12:30 ET
FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations
2020-08-31 12:30 ET
Simulations Plus to Present at the LD 500 Virtual Conference
2020-08-10 20:01 ET
Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-08-06 02:28 ET
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
2020-08-04 11:00 ET
Simulations Plus Announces Proposed Underwritten Public Offering
2020-07-09 20:05 ET
Simulations Plus Reports Third Quarter FY2020 Financial Results
2020-07-02 12:30 ET
Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call
2020-05-28 12:30 ET
Simulations Plus Receives New Grant Award from the FDA
2020-05-21 12:30 ET
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
2020-05-13 12:30 ET
Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference
2020-05-06 12:30 ET
U.S. FDA Renews Annual DILIsym Software Licenses
2020-04-09 20:35 ET
Simulations Plus Reports Record Second Quarter FY2020 Revenue
2020-04-07 12:30 ET
 Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®
2020-04-02 20:15 ET
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
2020-04-02 12:30 ET
Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
2020-03-26 17:46 ET
Simulations Plus Offers Rapid Response COVID-19 Research Initiative
2020-03-18 12:30 ET
Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team
2020-02-04 13:30 ET
DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure
2020-01-13 10:30 ET
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
2020-01-09 21:05 ET
Simulations Plus Reports Record First Quarter FY2020 Financial Results
2020-01-03 13:30 ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2020 Earnings Release and Conference Call
2019-12-05 13:30 ET
Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
2019-11-21 13:30 ET
Simulations Plus Partners with Large Pharmaceutical Company to Add New Capabilities to PKPlus
2019-11-14 13:30 ET
Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus
2019-11-13 21:05 ET
Simulations Plus Reports FY2019 and Fourth Quarter FY2019 Financial Results
2019-11-06 13:30 ET
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2019 Earnings Release and Conference Call
2019-10-29 12:30 ET
Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling
2019-10-17 12:30 ET
Simulations Plus Partners with Large Pharmaceutical Company to Develop the Virtual Bioequivalence Trial Simulator™ Module
2019-10-14 18:30 ET
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
2019-10-02 12:30 ET
Simulations Plus Announces Leadership Changes at Cognigen

SEC forms

Show financial reports only

SEC form 10
2026-04-10 20:05 ET
Simulations Plus published news for 2026 q1
SEC form 8
2026-04-09 20:06 ET
Simulations Plus published news for 2026 q1
SEC form 8
2026-04-09 20:06 ET
Simulations Plus published news for 2026 q1
SEC form 8
2026-04-09 20:06 ET
Simulations Plus published news for 2026 q1
SEC form 10
2026-01-09 21:07 ET
Simulations Plus published news for 2025 q4
SEC form 8
2026-01-08 16:07 ET
Simulations Plus published news for 2025 q4
SEC form 8
2026-01-08 16:07 ET
Simulations Plus reported for 2025 q4
SEC form 8
2026-01-08 16:07 ET
Simulations Plus published news for 2025 q4
SEC form 10
2025-12-01 16:16 ET
Simulations Plus reported for 2025 q3
SEC form 8
2025-12-01 16:06 ET
Simulations Plus published news for 2025 q3
SEC form 8
2025-12-01 16:06 ET
Simulations Plus reported for 2025 q3
SEC form 8
2025-12-01 16:06 ET
Simulations Plus published news for 2025 q3
SEC form 8
2025-10-22 11:51 ET
Simulations Plus published news for 2025 q3
SEC form 8
2025-10-22 11:51 ET
Simulations Plus reported for 2025 q3
SEC form 10
2025-07-15 12:02 ET
Simulations Plus reported for 2025 q2
SEC form 8
2025-07-15 11:56 ET
Simulations Plus published news for 2025 q2
SEC form 8
2025-07-15 11:56 ET
Simulations Plus published news for 2025 q2
SEC form 10
2025-07-15 00:00 ET
Simulations Plus reported for 2025 q2
SEC form 8
2025-07-14 20:49 ET
Simulations Plus published news for 2025 q2
SEC form 8
2025-07-14 20:49 ET
Simulations Plus reported for 2025 q2
SEC form 8
2025-07-14 20:49 ET
Simulations Plus published news for 2025 q2
SEC form 8
2025-06-18 20:08 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-06-18 20:08 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-06-12 13:28 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-06-12 13:28 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-06-11 20:38 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-06-11 20:38 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-04-18 12:34 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-04-18 12:34 ET
Simulations Plus published news for 2025 q1
SEC form 10
2025-04-04 11:55 ET
Simulations Plus reported for 2025 q1
SEC form 10
2025-04-04 00:00 ET
Simulations Plus reported for 2025 q1
SEC form 8
2025-04-03 20:05 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-04-03 20:05 ET
Simulations Plus reported for 2025 q1
SEC form 8
2025-04-03 20:05 ET
Simulations Plus published news for 2025 q1
SEC form 8
2025-02-18 21:50 ET
Simulations Plus published news for 2024 q4
SEC form 10
2025-01-08 00:00 ET
Simulations Plus reported for 2024 q4
SEC form 8
2025-01-07 16:06 ET
Simulations Plus published news for 2024 q4
SEC form 8
2025-01-07 16:06 ET
Simulations Plus reported for 2024 q4
SEC form 8
2025-01-07 16:06 ET
Simulations Plus published news for 2024 q4
SEC form 10
2024-10-30 00:00 ET
Simulations Plus reported for 2024 q3
SEC form 8
2024-10-23 16:06 ET
Simulations Plus published news for 2024 q3
SEC form 8
2024-10-23 16:06 ET
Simulations Plus reported for 2024 q3
SEC form 8
2024-10-23 16:06 ET
Simulations Plus published news for 2024 q3
SEC form 10
2024-07-08 00:00 ET
Simulations Plus reported for 2024 q2
SEC form 8
2024-07-02 16:08 ET
Simulations Plus published news for 2024 q2
SEC form 8
2024-07-02 16:08 ET
Simulations Plus reported for 2024 q2
SEC form 8
2024-07-02 16:08 ET
Simulations Plus published news for 2024 q2
SEC form 10
2024-04-05 00:00 ET
Simulations Plus reported for 2024 q1
SEC form 8
2024-04-03 16:06 ET
Simulations Plus published news for 2024 q1
SEC form 8
2024-04-03 16:06 ET
Simulations Plus reported for 2024 q1
SEC form 8
2024-04-03 16:06 ET
Simulations Plus published news for 2024 q1
SEC form 10
2024-01-05 00:00 ET
Simulations Plus reported for 2023 q4
SEC form 8
2024-01-03 16:06 ET
Simulations Plus published news for 2023 q4
SEC form 8
2024-01-03 16:06 ET
Simulations Plus reported for 2023 q4
SEC form 8
2024-01-03 16:06 ET
Simulations Plus published news for 2023 q4
SEC form 8
2024-01-03 16:06 ET
Simulations Plus published news for 2023 q4
SEC form 10
2023-10-27 00:00 ET
Simulations Plus published news for 2023 q3
SEC form 8
2023-10-25 16:06 ET
Simulations Plus reported for 2023 q3
SEC form 6
2023-07-07 16:25 ET
Simulations Plus published news for 2023 q2
SEC form 10
2023-07-07 06:08 ET
Simulations Plus published news for 2023 q2
SEC form 10
2023-07-07 00:00 ET
Simulations Plus published news for 2023 q2
SEC form 6
2023-07-06 16:06 ET
Simulations Plus reported for 2023 q2
SEC form 8
2023-07-06 00:00 ET
Simulations Plus published news for 2023 q2
SEC form 6
2023-06-20 08:00 ET
Simulations Plus published news for 2023 q1
SEC form 10
2023-04-07 08:51 ET
Simulations Plus reported for 2023 q1
SEC form 10
2023-04-07 00:00 ET
Simulations Plus reported for 2023 q1
SEC form 6
2023-04-05 16:07 ET
Simulations Plus published news for 2023 q1
SEC form 8
2023-04-05 00:00 ET
Simulations Plus reported for 2023 q1
SEC form 6
2023-03-07 09:11 ET
Simulations Plus published news for 2022 q4
SEC form 6
2023-02-13 16:40 ET
Simulations Plus published news for 2022 q4
SEC form 6
2023-01-11 17:37 ET
Simulations Plus published news for 2022 q4
SEC form 10
2023-01-06 16:04 ET
Simulations Plus reported for 2022 q4
SEC form 10
2023-01-06 00:00 ET
Simulations Plus reported for 2022 q4
SEC form 6
2023-01-04 16:09 ET
Simulations Plus published news for 2022 q4
SEC form 8
2023-01-04 00:00 ET
Simulations Plus reported for 2022 q4
SEC form 6
2022-12-23 07:55 ET
Simulations Plus published news for 2022 q3
SEC form 6
2022-11-07 13:45 ET
Simulations Plus published news for 2022 q3
SEC form 10
2022-10-28 08:23 ET
Simulations Plus reported for 2022 q3
SEC form 10
2022-10-28 00:00 ET
Simulations Plus reported for 2022 q3
SEC form 6
2022-10-26 16:06 ET
Simulations Plus published news for 2022 q3
SEC form 6
2022-10-26 08:11 ET
Simulations Plus published news for 2022 q3
SEC form 8
2022-10-26 00:00 ET
Simulations Plus reported for 2022 q3
SEC form 6
2022-10-24 19:04 ET
Simulations Plus published news for 2022 q3
SEC form 6
2022-10-24 19:02 ET
Simulations Plus published news for 2022 q3
SEC form 6
2022-10-20 16:15 ET
Simulations Plus published news for 2022 q3
SEC form 6
2022-09-14 14:00 ET
Simulations Plus published news for 2022 q2
SEC form 6
2022-08-02 17:14 ET
Simulations Plus published news for 2022 q2
SEC form 6
2022-08-02 17:13 ET
Simulations Plus published news for 2022 q2
SEC form 10
2022-07-08 11:36 ET
Simulations Plus reported for 2022 q2
SEC form 10
2022-07-08 00:00 ET
Simulations Plus reported for 2022 q2
SEC form 6
2022-07-06 16:06 ET
Simulations Plus published news for 2022 q2
SEC form 8
2022-07-06 00:00 ET
Simulations Plus reported for 2022 q2
SEC form 6
2022-04-26 09:00 ET
Simulations Plus published news for 2022 q1
SEC form 10
2022-04-08 16:10 ET
Simulations Plus reported for 2022 q1
SEC form 10
2022-04-08 00:00 ET
Simulations Plus reported for 2022 q1
SEC form 6
2022-04-06 17:06 ET
Simulations Plus published news for 2022 q1
SEC form 8
2022-04-06 00:00 ET
Simulations Plus reported for 2022 q1
SEC form 6
2022-02-15 16:01 ET
Simulations Plus published news for 2021 q4
SEC form 6
2022-02-14 16:41 ET
Simulations Plus published news for 2021 q4
SEC form 6
2022-01-19 16:13 ET
Simulations Plus published news for 2021 q4
SEC form 10
2022-01-07 16:15 ET
Simulations Plus published news for 2021 q4
SEC form 10
2022-01-07 00:00 ET
Simulations Plus published news for 2021 q4
SEC form 6
2022-01-06 17:00 ET
Simulations Plus published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
Simulations Plus published news for 2021 q4
SEC form 6
2021-12-17 16:10 ET
Simulations Plus published news for 2021 q3
SEC form 6
2021-11-19 09:15 ET
Simulations Plus published news for 2021 q3
SEC form 10
2021-10-27 16:15 ET
Simulations Plus published news for 2021 q3
SEC form 10
2021-10-27 00:00 ET
Simulations Plus published news for 2021 q3
SEC form 6
2021-10-25 14:10 ET
Simulations Plus published news for 2021 q3
SEC form 8
2021-10-25 00:00 ET
Simulations Plus published news for 2021 q3
SEC form 6
2021-10-13 16:02 ET
Simulations Plus published news for 2021 q3
SEC form 6
2021-09-21 15:18 ET
Simulations Plus published news for 2021 q2
SEC form 10
2021-07-14 16:05 ET
Simulations Plus published news for 2021 q2
SEC form 10
2021-07-14 00:00 ET
Simulations Plus published news for 2021 q2
SEC form 6
2021-07-12 16:05 ET
Simulations Plus published news for 2021 q2
SEC form 6
2021-06-25 16:05 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-06-11 15:04 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-06-10 12:56 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-06-08 14:28 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-05-20 14:00 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-05-11 16:44 ET
Simulations Plus published news for 2021 q1
SEC form 10
2021-04-14 16:05 ET
Simulations Plus published news for 2021 q1
SEC form 10
2021-04-14 00:00 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-04-12 16:05 ET
Simulations Plus published news for 2021 q1
SEC form 6
2021-03-01 16:01 ET
Simulations Plus published news for 2020 q4
SEC form 6
2021-02-18 16:01 ET
Simulations Plus published news for 2020 q4
SEC form 6
2021-01-15 16:05 ET
Simulations Plus published news for 2020 q4
SEC form 10
2021-01-11 17:20 ET
Simulations Plus published news for 2020 q4
SEC form 6
2021-01-11 17:15 ET
Simulations Plus published news for 2020 q4
SEC form 6
2021-01-04 07:57 ET
Simulations Plus published news for 2020 q4
SEC form 6
2020-12-29 07:52 ET
Simulations Plus published news for 2020 q3
SEC form 6
2020-12-18 07:58 ET
Simulations Plus published news for 2020 q3
SEC form 6
2020-12-17 17:03 ET
Simulations Plus published news for 2020 q3
SEC form 6
2020-12-01 17:15 ET
Simulations Plus published news for 2020 q3
SEC form 6
2020-11-16 20:05 ET
Simulations Plus published news for 2020 q3
SEC form 10
2020-11-16 17:20 ET
Simulations Plus published news for 2020 q3
SEC form 6
2020-10-13 16:30 ET
Simulations Plus published news for 2020 q3